Most cited papers from Jeuk (South Korea)

Jeuk (South Korea)

What are the most cited papers from Jeuk (South Korea)?

The most cited paper from Jeuk (South Korea) is "Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer" (Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo et al., 2019), with 305 citations. Next come "Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC" (300) and "Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer" (293).

Published FieldAccessCitations

Showing 48 of 48 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo et al. · Annals of Oncology Open access	6 Apr 2019	305
2	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC Jiyeon Yun, Soo‐Hwan Lee, Seok-Young Kim et al. · Cancer Discovery Open access	15 May 2020	300
3	Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer Jae-Won Cho, Min Hee Hong, Sang‐Jun Ha et al. · Experimental & Molecular Medicine Open access	Sep 2020	293
4	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients Hye Ryun Kim, Sang‐Jun Ha, Min Hee Hong et al. · Scientific Reports Open access	14 Nov 2016	262
5	YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer Jiyeon Yun, Min Hee Hong, Seok‐Young Kim et al. · Clinical Cancer Research Open access	22 Jan 2019	133
6	Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer Mi Ran Yun, Dong Hwi Kim, Seok‐Young Kim et al. · Clinical Cancer Research Open access	13 Apr 2020	121
7	The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti–PD-1 Therapy in Patients with Non–Small Cell Lung Cancer Hye Ryun Kim, Su-Myeong Park, Sang‐Uk Seo et al. · American Journal of Respiratory and Critical Care Medicine Open access	19 Oct 2018	102
8	Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition Hyo Song Kim, Minkyu Jung, Hari Kang et al. · Oncogene Open access	16 Jan 2017	98
9	Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma Min Hwan Kim, Hyo Sup Shim, Dae Ryong Kang et al. · Lung Cancer Open access	14 Jan 2014	65
10	Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer Je-In Youn et al. · Scientific Reports Open access	3 Jun 2020	64
11	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer Mi Ran Yun, Hun Mi Choi, You Won Lee et al. · EMBO Molecular Medicine Open access	21 Oct 2019	63
12	Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy S-M Kim, Hyeon-Deok Kim, H Kim et al. · Oncogenesis Open access	18 Jul 2016	61
13	The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression Jaebeom Cho, HJ Lee, Su Jung Hwang et al. · Cancer Research	19 Mar 2020	49
14	Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer Chang Gon Kim, Min Hee Hong, Kyung Hwan Kim et al. · European Journal of Cancer	7 Dec 2020	48
15	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors Mi Ran Yun et al. · Cancer Research Open access	18 Apr 2018	46
16	Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy Eun‐Ah Choe, Yoon Jin Cha, Jae Hwan Kim et al. · Lung Cancer Open access	Aug 2019	43
17	Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation Hyeong Jung Woo et al. · Theranostics Open access	2022	40
18	Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck Hye Ryun Kim et al. · British Journal of Cancer Open access	23 Sep 2020	38
19	Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma Seok‐Young Kim, Ji Yeon Lee, Donghwi Kim et al. · Scientific Reports Open access	27 Dec 2019	36
20	ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma Mi Ran Yun, Hyantae Choi, Hari Kang et al. · Oncogene Open access	25 Sep 2017	36
21	Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma Sun Min Lim, Jae Woo Choi, Min Hee Hong et al. · Lung Cancer Open access	3 Apr 2019	35
22	Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer Beung‐Chul Ahn et al. · European Journal of Cancer Open access	25 Jun 2021	34
23	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation Han Na Kang et al. · Lung Cancer Open access	11 Aug 2018	34
24	Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer Ye‐Jin Kim, Ye-Jin Kim, Du-San Baek et al. · Cancer Letters Open access	12 Sep 2019	33
25	Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer Han Na Kang et al. · BMC Cancer Open access	15 Apr 2020	29
26	Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck Kie Kyon Huang et al. · Scientific Reports Open access	21 Jan 2016	28
27	BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer Sun Min Lim, Stefanie S. Schalm, Eun Ji Lee et al. · Therapeutic Advances in Medical Oncology Open access	2024	24
28	Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization Hye Ryun Kim, Yoon Jin Cha, Min Hee Hong et al. · Oncotarget Open access	14 Aug 2017	20
29	Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET -Rearranged Lung Adenocarcinoma Chan Woo Kang, Kang Won Jang, Jinyoung Sohn et al. · Molecular Cancer Therapeutics Open access	24 Jul 2015	20
30	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor Chun‐Bong Synn, Dong Kwon Kim, Jae Hwan Kim et al. · Yonsei Medical Journal Open access	15 Dec 2021	18
31	SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models Chun‐Bong Synn et al. · Clinical & Translational Immunology Open access	29 Dec 2021	16
32	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma Min Hee Hong, Seong Gu Heo, Yun‐Gyoo Lee et al. · Cancer Open access	4 Aug 2020	16
33	CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production Kwangmin Na et al. · Frontiers in Immunology Open access	7 Mar 2024	14
34	Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma Sun Min Lim et al. · Cancer Research Communications Open access	25 Jun 2024	11
35	The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC Seung Yeon Oh, Sewon Park, Seo-Young Lee et al. · Cell Reports Medicine Open access	27 Jan 2025	10
36	Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity Wongeun Lee et al. · Frontiers in Oncology Open access	9 Mar 2022	10
37	ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models Han Na Kang, Se-Ho Kim, Mi Ran Yun et al. · Lung Cancer Open access	28 Feb 2016	7
38	Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme Sun Min Lim, Junjeong Choi, Jong Hee Chang et al. · PLoS ONE Open access	14 Sep 2015	6
39	Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types Dong Kwon Kim, Chai Young Lee, Yu Jin Han et al. · Frontiers in Immunology Open access	12 Apr 2024	5
40	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma Han Sang Kim, Hye Ryun Kim, Gun Min Kim et al. · Cancer Chemotherapy and Pharmacology	6 Aug 2012	5
41	Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab Dong Kwon Kim et al. · Molecular Cancer Therapeutics Open access	5 Dec 2024	4
42	Mutation-Driven Immune Microenvironments in Non-Small Cell Lung Cancer: Unrevealing Patterns through Cluster Analysis Youngtaek Kim, Joon Yeon Hwang, Kwangmin Na et al. · Yonsei Medical Journal Open access	2024	4
43	YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment Dong Kwon Kim et al. · Frontiers in Chemistry Open access	5 Dec 2022	4
44	RNA silencing components mediate resistance signaling against turnip crinkle virus Shifeng Zhu, Gah‐Hyun Lim, Keshun Yu et al. · Plant Signaling & Behavior Open access	Mar 2014	4
45	Modeling the metastatic tumor microenvironment: a co-culture platform of lung cancer and blood vessel organoids for drug evaluation Mingyun Lee, Yeojoon Yoon, Ji Yeon Lee et al. · Scientific Reports Open access	24 Nov 2025	3
46	Exploring the Expression and Function of T Cell Surface Markers Identified through Cellular Indexing of Transcriptomes and Epitopes by Sequencing Joon Yeon Hwang, Youngtaek Kim, Kwangmin Na et al. · Yonsei Medical Journal Open access	2024	3
47	Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies Youngtaek Kim, Joon Yeon Hwang, Dong Kwon Kim et al. · Cancers Open access	21 Sep 2023	1
48	P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC Jun-Won Yun, Hari Kang, S. Lee et al. · Journal of Thoracic Oncology Open access	Oct 2019	1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.